ALK-Abelló
203.80 DKK
+2.05 %
Less than 1K followers
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.05 %
-2.77 %
-10.85 %
-10.46 %
+0.89 %
+45.57 %
+100.00 %
+79.72 %
+490.72 %
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Read moreMarket cap
45.41B DKK
Turnover
44.95M DKK
Revenue
6.31B
EBIT %
26.2 %
P/E
37.74
Dividend yield-%
0.79 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.5
2026
Interim report Q1'26
20.8
2026
Interim report Q2'26
18.11
2026
Interim report Q3'26
All
Research
Webcasts
Press releases
ShowingAll content types
Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
